Date: 2016-06-06
Type of information: Collaboration agreement
Compound:
Company: Moderna Therapeutics (USA - MA) Charles River (USA - MA)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On June 6, 2016, Moderna Therapeutics, a clinical stage pioneer in the development of messenger RNA (mRNA) Therapeutics™ and Charles River Laboratories International announced a strategic collaboration to support Moderna’s nonclinical discovery and development efforts. Charles River will be a key partner as Moderna continues to grow and advance its pipeline spanning multiple drug modalities and therapeutic areas, conducting nonclinical activities to progress development candidates through investigational new drug (IND)-enabling studies and into the clinic.
Moderna Therapeutics has currently ten programs in development across its internal efforts and external collaborations. This collaboration will allow Moderna Therapeutics to accelerate GLP toxicology study timelines. Moderna’s current modalities include infectious disease vaccines, personalized cancer vaccines, rare disease-associated intracellular/transmembrane liver proteins, intratumoral cancer therapy, and secreted antibodies and proteins. Moderna is leveraging these modalities to advance drugs across a broad spectrum of therapeutic areas via its wholly owned ventures as well as a growing ecosystem of partners.
Financial terms:
Latest news:
